Tff Pharmaceuticals is a biotechnology business based in the US. Tff Pharmaceuticals shares (TFFP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.34 – a decrease of 9.55% over the previous week. Tff Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around $1.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.34 |
|---|---|
| 52-week range | $0.27 - $11.00 |
| 50-day moving average | $2.02 |
| 200-day moving average | $3.17 |
| Wall St. target price | $30.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.88 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3402 from 2024-11-22
| 1 week (2024-11-15) | -9.55% |
|---|---|
| 1 month (2024-10-24) | -83.49% |
| 3 months (2024-08-23) | -84.74% |
| 6 months (2024-05-23) | -83.32% |
| 1 year (2023-11-22) | 14.16% |
|---|---|
| 2 years (2022-11-23) | -98.99% |
| 3 years (2021-11-23) | 185.25 |
| 5 years (2019-11-22) | 128.5 |
| Revenue TTM | $1.2 million |
|---|---|
| Gross profit TTM | $-21,212,704 |
| Return on assets TTM | -105.91% |
| Return on equity TTM | -213.51% |
| Profit margin | 0% |
| Book value | $1.81 |
| Market Capitalization | $1.3 million |
TTM: trailing 12 months
We're not expecting Tff Pharmaceuticals to pay a dividend over the next 12 months.
Tff Pharmaceuticals's shares were split on a 1:25 basis on 18 December 2023 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tff Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Tff Pharmaceuticals shares which in turn could have impacted Tff Pharmaceuticals's share price.
Over the last 12 months, Tff Pharmaceuticals's shares have ranged in value from as little as $0.27 up to $11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tff Pharmaceuticals's is 1.316. This would suggest that Tff Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TFF Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.